EFPIA Disclosure Code 2016 Disclosures Shire Pharmaceuticals (including Baxalta US Inc.)

Similar documents
European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements Methodology Note for Shire

European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements. Biogen Methodology Note

European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Transparency Requirements. Biogen Methodology Note

Methodological Note. - Merck Oy Finland -

This document explains the methodology underlying Roche s EFPIA disclosure

Mitsubishi Tanabe Pharma Group Methodology. Transfers of Value to Healthcare Professionals (HCP) and Healthcare Organisations (HCO) in Europe

Medicines for Europe (MFE) HCP/HCO/PO Disclosure Transparency Requirements. Samsung Bioepis Methodology Note

EFPIA HCP/HCO DISCLOSURE CODE

Agenda. EFPIA Disclosure Rules - Basics Latest Developments in Transcription As of 1/15/14

Spain France. England Netherlands. Wales Ukraine. Republic of Ireland Czech Republic. Romania Albania. Serbia Israel. FYR Macedonia Latvia

Approach to Employment Injury (EI) compensation benefits in the EU and OECD

RULES FOR THE REIMBURSEMENT OF TRAVEL AND SUBSISTENCE EXPENSES FOR EXCHANGE OF OFFICIALS

MedTech Europe Code of Ethical Business Practice. Disclosure Guidelines

EU-28 RECOVERED PAPER STATISTICS. Mr. Giampiero MAGNAGHI On behalf of EuRIC

Methodology for Compliance with the Research-Based Pharmaceutical Industry (LIF) Disclosure Code

CODE FOR DISCLOSURE OF TRANSFERS OF VALUE BY PHARMACEUTICAL COMPANIES TO HEALTHCARE PROFESSIONALS AND HEALTH ORGANIZATIONS

Methodology for Compliance with the ABPI Disclosure Code. Introduction Page 1. General Comments Page 2. Indirect Transfers of Value Page 3

Pfizer Hellas SA PRIMA/EFPIADisclosure Code Transparency Report

European Advertising Business Climate Index Q4 2016/Q #AdIndex2017

EU BUDGET AND NATIONAL BUDGETS

Pfizer 2015 Disclosure Code Transparency Report

How to complete a payment application form (NI)

Pharma Cooperation Code Transparency Report Methodological Note. Pfizer Switzerland

FCCC/SBI/2010/10/Add.1

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2017 New Methodological Note

Summary of key findings

EFPIA Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations

11 th Economic Trends Survey of the Impact of Economic Downturn

Electricity & Gas Prices in Ireland. Annex Business Electricity Prices per kwh 2 nd Semester (July December) 2016

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Slovenia Country Profile

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

Any healthcare professional and healthcare organization whose primary practice, principal professional address or place of incorporation

Online Insurance Europe: BEST PRACTICES & TRENDS

Live Long and Prosper? Demographic Change and Europe s Pensions Crisis. Dr. Jochen Pimpertz Brussels, 10 November 2015

Lithuania: in a wind of change. Robertas Dargis President of the Lithuanian Confederation of Industrialists

NOTE. for the Interparliamentary Meeting of the Committee on Budgets

EU State aid: Guidelines on State aid for environmental protection and energy making of -

AstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2015 Data in 2016

Borderline cases for salary, social contribution and tax

Any healthcare professional and healthcare organisation whose primary practice, principal professional address or place of incorporation

DG TAXUD. STAT/11/100 1 July 2011

Dividends from the EU to the US: The S-Corp and its Q-Sub. Peter Kirpensteijn 23 September 2016

Novartis Methodological Note

Learn more about Thresholds

Novartis Methodological Note

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

InnovFin SME Guarantee

Gilead Transparency Reporting Methodological Note

DOCUMENT HISTORY. Supersedes / Replaces. Version Effective Date Summary of Changes 01 30JUN2016 New Methodological Note

Report Penalties and measures imposed under the UCITS Directive in 2016 and 2017

Pfizer 2016 Disclosure Code Transparency Report

DPD CLASSIC (Slovenia) Slovenia 6,00 7,00 10,00 11,00 12,00 13,00 14,00 16,00 18,00 DPD CLASSIC - PARCEL DELIVERY TO THE EU

EUROPA - Press Releases - Taxation trends in the European Union EU27 tax...of GDP in 2008 Steady decline in top corporate income tax rate since 2000

Novartis Methodological Note

Statistics: Fair taxation of the digital economy

Quarterly Gross Domestic Product of Montenegro 2st quarter 2016

EMPLOYMENT RATE Employed/Working age population (15-64 years)

Quarterly Gross Domestic Product of Montenegro 3 rd quarter 2017

List of nationally authorised medicinal products

Pfizer 2017 Disclosure Code Transparency Report

The Architectural Profession in Europe 2012

Latvia Country Profile

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Novartis Methodological Note

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Aim Higher EUROSTARS. Funding excellence in innovation. Eligibility guidelines for applications. December 2015 Version 2.0

Transfer of Value Disclosure Report as per National Legislation

Lithuania Country Profile

CANADA EUROPEAN UNION

Reporting practices for domestic and total debt securities

AstraZeneca AB Södertälje. Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Novartis Methodological Note

EIOPA Statistics - Accompanying note

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

FY18 Campaign Terms. CAMPAIGN AGREEMENT ( Campaign Agreement ) FOR CEE DYNAMICS 365 CSP CAMPAIGN ( Program )

Macroeconomic scenarios for skill demand and supply projections, including dealing with the recession

Gilead Transparency Reporting Methodological Note

Lowest implicit tax rates on labour in Malta, on consumption in Spain and on capital in Lithuania

2017 Figures summary 1

Tax Card 2018 Effective from 1 January 2018 The Republic of Estonia

June 2014 Euro area international trade in goods surplus 16.8 bn 2.9 bn surplus for EU28

FOREWORD. Estonia. Services provided by member firms include:

LENDING FACILITIES Hire Purchase (HP) 1% % on a case by case basis (fee set by AgriFinance Ltd)

Gilead Transparency Reporting Methodological Note

TAXATION OF TRUSTS IN ISRAEL. An Opportunity For Foreign Residents. Dr. Avi Nov

Call for proposals. for civil society capacity building and monitoring of the implementation of national Roma integration strategies

EIOPA Statistics - Accompanying note

EUREKA Programme A European Research Programme. > Not an EU-Programme (but complementarity and co-operation - ERA)

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Gilead Transparency Reporting Methodological Note

IN AN EMERGENCY / 2015

Comparing pay trends in the public services and private sector. Labour Research Department 7 June 2018 Brussels

Enterprise Europe Network SME growth outlook

GUIDE FOR THE REIMBURSEMENT OF TRAVEL AND ACCOMMODATION EXPENSES AND PAYMENT OF SUBSISTENCE ALLOWANCES

Open Day 2017 Clearstream execution-to-custody integration Valentin Nehls / Jan Willems. 5 October 2017

EIOPA Statistics - Accompanying note

Novartis Methodological Note

Title: Methodological Note

Economic and Social Council

Transcription:

EFPIA Disclosure Code 2016 Disclosures Shire Pharmaceuticals (including Baxalta US Inc.) 1

Section 1: Reporting Approach for 2016 Data: On June 3rd, 2016, Shire acquired Baxalta. Due to the complexity of integration between the two companies, Shire has made the decision to disclose as two separate entities for the disclosure period of 2016. As such, Shire would like to highlight the key differences in methodology between the two companies. Shire will disclose based on a consistent methodology where possible for data collected in 2017 and published in 2018. Section 2: Scope of Disclosure: The following EFPIA member countries are in scope for disclosure: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine and the United Kingdom. Per EFPIA, the following countries have a full or partial exception to the Disclosure Code: 1. Denmark 2. France 3. Netherlands 4. Portugal 5. Slovakia 6. Turkey Shire will publish data based on the local country Code template. If no template is provided by the local country, then Shire will default to the EFPIA Disclosure Code template. Section 3: Key Decisions & Differences in Methodology: Below captures the decisions that drive our collection, aggregation and reporting process and identifies where there are differences between Shire and Baxalta for 2016 data: Decision Point Shire s Approach Baxalta s Approach Tax & VAT Austria: VAT is excluded for direct Belgium: VAT is excluded for direct payments including sponsorships and Austria: VAT is excluded. Belgium: VAT is excluded for honorarium associated with consultancy payments and sponsorships and included for in kind 2

included for in kind Bulgaria: VAT is excluded for direct Croatia: VAT is excluded for direct Cyprus: Follows local guidance. Czech Republic: VAT is excluded for direct payments and included for in kind Estonia: VAT is excluded for direct Finland: VAT is excluded for direct Germany: VAT is excluded for direct Greece: VAT is excluded for direct Hungary: VAT is excluded for direct Iceland: VAT is excluded for direct Ireland: VAT is excluded for direct Italy: VAT is excluded for direct Latvia: VAT is excluded for direct Bulgaria: VAT is excluded for direct Croatia: VAT is excluded for direct Czech Republic: VAT is excluded for direct payments and included for in kind Estonia: VAT is included. Finland: VAT is excluded. Germany: VAT is excluded. Greece: VAT is excluded for direct Hungary: VAT is excluded for direct Ireland: VAT is excluded for direct Italy: VAT is excluded for direct VAT is included for transfers of value not approved by Italian Medicines Agency (AIFA). Lithuania: VAT is included. The Netherlands: VAT is excluded for direct payments including sponsorships and included for in kind Norway: VAT is excluded. Poland: VAT is excluded for direct transfers of value excepting for 3

Lithuania: VAT is excluded for direct Luxembourg: VAT is excluded for direct payments including sponsorships and included for in kind Malta: VAT is excluded for direct The Netherlands: VAT is excluded for direct payments including sponsorships and included for in kind Norway: VAT is excluded for direct Poland: For honorarium associated with services and consultancy, Shire will report the full invoice amount including withholding (personal income) tax. VAT is excluded for other direct payments and included for the majority of in kind Romania: VAT is excluded for direct Russia: For honorarium associated with services and consultancy, Shire will report the full invoice amount including withholding (personal income) tax. For costs related to Events (such as registration fees, travel and accommodation), Shire will report the full invoice amount including VAT. Serbia: VAT is excluded for direct Slovakia: VAT is excluded for direct Registration Fees. Romania: VAT is excluded for direct Serbia: VAT is excluded for direct Slovakia: VAT is excluded for direct Slovenia: VAT is excluded for direct Spain: VAT is excluded for direct Sweden: VAT is excluded. Switzerland: VAT is excluded. Ukraine: For services and Consultancy, VAT is excluded unless local Code or Law explicitly requires otherwise. For costs related to Events (such as registration fees, travel and accommodation), VAT is included. Where there is a withholding tax, Shire will report the full invoice amount. United Kingdom: VAT is excluded for direct payments and included for in kind 4

Disclosure Currency Transfer of Value Dates Slovenia: VAT is excluded for direct Spain: For honorarium associated with services and consultancy, Shire will report the full invoice amount including withholding (personal income) tax. VAT is excluded for all other payments. Sweden: VAT is excluded for direct Switzerland: VAT is excluded for direct Ukraine: For honorarium associated with services and consultancy, Shire will report the full invoice amount including withholding (personal income) tax. For costs related to Events (such as registration fees, travel and accommodation), Shire will report the full invoice amount including VAT. United Kingdom: VAT is excluded for direct payments and included for in kind All payments and transfers of value will be disclosed in local currency per guidance from EFPIA. If a payment is captured in another currency, it will be converted into local country currency based on the date at which the transfer of value occurred and corresponding daily exchange rate. Shire used the payment date for direct Fee For Service and other payments for activities within the reporting Baxalta used the payment date for direct Fee For Service and other payments for activities within the 5

Reconciliation of the Data Cancellation of events or contracts including when a HCP does not participate Disclosure of Cross-Border Transfers of Value period and applied the event date for all other transfers of values like Travel & Lodging. For contracts with services that span multiple periods, Shire used the date of payment as the transfer of value date. For Italy, based on guidance from the local association, Shire used payment date for all On an annual basis, Shire will complete a full year reconciliation to identify any transactions that were submitted post data validation or post publication and update the reports accordingly to support the principles of full transparency. Shire will only attribute the transfers of value that are incurred and can be reasonably associated to the HCP based on supporting documentation. In the circumstances when a flight or accommodation is booked but the event is cancelled or HCP does not attend, no transfer of value will be attributed to that HCP. Shire will disclose based on the principal practice address of the recipient. Shire relies on IMS as a recognized industry leader in data management to determine the principal practice address of the HCP and HCO to be consistent across the EFPIA countries. This may not match with the address collected on the contract, in our finance system of payment or in our reporting period and applied the event date for all other transfers of value like Travel & Lodging. For a minority of reportable transactions, where event dates were not available, the payment date has been applied for transfers of value like Travel & Lodging. For contracts with services that span multiple periods, Baxalta used the date of payment as the transfer of value date. As Baxalta is now part of Shire, all transfers of value for the 2016 reporting period will be part of the annual reconciliation of data process. 6

Disclosure Language Disclosure of Local Identifiers Charitable Contributions Payment made to Institution (as an travel grant) and the HCO sends a HCP to an event other supporting documentation. All disclosures will be made available in English on our public website (Shire.com) but primarily made in the language(s) prescribed in the national codes. To support the principles of privacy, Shire will disclose the Country Unique Identifier for HCPs and/or HCOs where this is required based on the local code. Shire followed the EFPIA guidance on the following: A donation or grant to a HCO will be disclosed as a Transfer of Value under the Donation/Grant section of the applicable Disclosure report. Sponsorships of a HCO will be disclosed as a Transfer of Value, under the Costs related to Events section of the applicable Disclosure report. Shire decided: 1. If a payment was made to a HCO for the benefit of HCPs and the identity of the HCP was attainable, Shire disclosed only once, and on an individual basis against the relevant HCPs and obtained the appropriate consent. 2. If a payment was made to the HCO and the identity of the HCP was unknown; Shire disclosed the transfer of value against the HCO under Costs related to Events. Country in Shire determined that the transfers of 7

which to report Research Payments value would be disclosed based on the principal address of the recipient regardless of where the payment is made. Section 4: Consent Management at Shire & Baxalta Shire Shire is collecting consent for each engagement with all HCPs (and HCOs where applicable) based on local requirements with the following exceptions: Spain has collected consent at the profile level for 2016 data. These are the decisions made to avoid the cherry picking of transactions for individual disclosure: If consent is given for all engagements, Shire will disclose transfers of value to the HCP under the individual section of the applicable Disclosure report. If Shire does not receive consent for all engagements, we will default all transfers of values to the aggregate section of the applicable Disclosure report. If the consent form is not returned to Shire, we will default all transfers of value to the aggregate section of the applicable Disclosure report. These are the decisions made for the revoking of individual consent: If a HCP or HCO revokes consent prior to publication of the data, Shire will update the data and include the transfers of value in the aggregate section of the applicable Disclosure report. Baxalta Baxalta is collecting consent for each engagement with all HCPs and HCOs (where applicable) based on local requirements with the following exceptions: 1. For Germany and Austria, consent is collected at the profile level once every 3 years. 2. For Estonia, Latvia and Lithuania, if no consent was given to disclose at an individual level, then Baxalta did not engage the HCP. There is no difference for the other points. 8

If a HCP or HCO revokes consent after publication of the data, Shire will update the information at the first reasonable time. Other Considerations for Belgium: For HCP s who do not have a RIZIV/INAMI number, all transfers of value will be reported in the aggregate. For HCO s who do not have an enterprise number, Shire has decided to declare the transfers of value at an aggregate level. Section 5: Submission Approach for 2016 Data The Disclosure Method for 2016 Data A. Shire will publish the disclosure file on our Shire.com website for the following countries: Bulgaria, Croatia, Estonia, Finland, Greece, Hungary, Iceland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden and Ukraine B. Shire will publish a link and/or the report on the local Shire website for the following countries: Austria, Bulgaria, Germany, Italy, Latvia, Lithuania, Norway, Romania, Russia, Serbia, Spain, Sweden, Switzerland, Ukraine C. Shire will publish on the central registry for the following countries: Czech Republic, Ireland, UK and Belgium D. The report for Cyprus will be published by the distributor and not by Shire. E. Shire will not publish an EFPIA Disclosure report for Turkey until further guidance is provided by EFPIA and the Turkish authorities The Timing of Disclosures for 2016 Shire will publish data for the prior period on or before June 30 unless the local Association sets a specific date. 9

Data Other dates include: A. The UK will be submitted by March 31 B. Belgium will be submitted by April 30 C. Estonia will be published by June 1 Section 6: Categories for Disclosure as Defined within the Code: Description Donations and Grants to Healthcare Organisations Research & Development (to be published in the aggregate section of the disclosure template) Contribution to costs of Events: Sponsorship agreements Contribution to cost of Events: Registration Fees Contribution to costs of Events: Travel & Accommodation Types of Transfer of Value Included Per EFPIA Donations and Grants to HCO s that support healthcare including donations, grants and benefits in kind. Research and Development transfer of values to HCPs/HCOs associated with: Non-clinical (Good Laboratory Practice (GLP) Clinical trials in Phase I to Phase IV Investigator sponsored studies Non-interventional studies Events include all scientific professional meetings, congresses, conferences, symposia and other similar events. Sponsorships with HCOs/third party appointed by an HCO to manage an Event. Registrations fees related to attending a Congress or Symposia paid to an HCO on behalf of an HCP disclosed on an individual basis (in the name of the HCO). Examples: Rental of booth space at an event Advertisement space Satellite symposia at a Congress Sponsoring of speakers/faculty Registrations fees related to attending a Congress or Symposia. 1. Travel expenses related to attending a Congress or Symposia. 2. Accommodation expenses related to attending a Congress or Symposia. Example: 10

Fees for airfare, train, boat or ferry (incl. booking fees) Car rental, car services, taxi transfers Parking fees Gas/Petrol costs Road tolls or fees Fee for service and consultancy: Fees Fee for service and consultancy: Related expenses agreed in the fee for service or consultancy contract Transfers of value resulting from or related to contracts between Member Companies and institutions, organisations, associations or HCPs under which such institutions, organisation, association or HCPs provide any type of services to a Member Company or any other type of funding not covered in the previous categories. Examples include: Speaker fees Speaker training Data analysis Development of education materials General Consulting/Advising Related expenses agreed in the fee for service or consultancy contract: Examples include: Fees for airfare, train, boat or ferry (incl. booking fees) Car rental, car services, taxi transfers Parking fees Gas/Petrol costs Road tolls or fees 11